Table 2 Overview of study populations and research aims of the included studies
Study | Age IBM patients* years | Age at onset/diagnosis* years | Disease Duration* years | Disease Severity* IBM specific | Disease severity measures** Others | Research Aims Regarding HRQoL and Mental Health/Illness |
|---|---|---|---|---|---|---|
Feldon et al. [34] | Not stated; | Not stated/Median 62.3 (IQR 55.5–68.2) | Median 9.2 (IQR 5.3–13.6) | Not stated | Questionnaire with disease-related information | HRQoL in adult IIM compared to RA and normal population, predictors of lower HRQoL in IIM |
Goyal et al. [36] | Median seropositive 67 (47–77), seronegative 70 (60–85) | Median seropositive: 55.5 (45–71), seronegative: 54.0 (54–78)/not stated | Median seropositive:10.0 (3–15), seronegative: 11.0 (4–24) | IBMFRS median seropositive: 23 (17–36), seronegative: 29 (22–35), (p = 0.06) | 6 min walk test, timed get up and stand test, MRC, right and left hand grip, NIF, pressure meter, mRS, mOBFRS | Exploring HRQoL according to NT5c1A antibody |
Rose et al. [39] | Mean 63 ± 11.6 | Not stated |  > 0.6 | Not stated | HAQ | Impact of chronic muscle disease upon HRQoL, exploring disease severity, mood and illness perceptions upon HRQoL |
Sadjadi et al. [38] | Mean 64.47 ± 8.47 | Not stated | Mean 4.35 ± 2.96 (0–10.8) | Not stated | ALS-FRS, MMT, QMT | Impact of IBM upon HRQoL, impact of disease severity upon HRQoL, identification of alternative assessments for IBM relating to HRQoL, impact of depression on relationship of disease severity and HRQoL |
Gibson et al. [35] | Mean 58.1 (50–80) | Not stated | Not stated | Not stated | Not stated | Impact of pertinent symptoms upon HRQOL and daily functions |
Ortega et al. [37] | Not stated; total study population (34–76) | Not stated | Not stated | Not stated | Not stated | Patients’ areas of concerns and impact of myositis upon daily living to discuss with rheumatologists |